SEC Comment Letter for Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Feb 4, 2010

Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: Feb. 4, 2010 · CIK: 0000072444 · Accession: 0000000000-10-007168

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-04829

Date

February 4, 2010

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

Vaxart, Inc. (VXRT) (CIK 0000072444)

Letter

Mail Stop 4720 February 4, 2010 Raafat E.F. Fahim, Ph.D. Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852 Re: Nabi Biopharmaceuticals Preliminary Proxy Statement on Schedule 14A Filed December 7, 2009, as amended February 3, 2010 File No. 000-04829 Dear Dr. Fahim: We have completed our review of the a bove proxy statement. We have no further comments at this time.

Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r

Show Raw Text

Mail Stop 4720
February 4, 2010
 Raafat E.F. Fahim, Ph.D. Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852
Re: Nabi Biopharmaceuticals
  Preliminary Proxy Statement on Schedule 14A
Filed December 7, 2009, as amended February 3, 2010
  File No. 000-04829
Dear Dr. Fahim:
  We have completed our review of the a bove proxy statement.  We have no further
comments at this time.

Sincerely,

          J e f f r e y  P .  R i e d l e r          A s s i s t a n t  D i r e c t o r

  cc:  Joseph E. Gilligan, Esq.         Hogan & Hartson LLP        Columbia Square        555 Thirteenth Street, NW        Washington, DC 20004

SecProbe.io